Name: LAPTM4B Antibody
Brand: CUSABIO
SKU: CSB-PA774814LA01HU

Product Details

Full Product Name

Rabbit anti-Homo sapiens (Human) LAPTM4B Polyclonal antibody

Uniprot No.

Q86VI4

Target Names

LAPTM4B

Alternative Names

LAPTM4B; PSEC0001; Lysosomal-associated transmembrane protein 4B; Lysosome-associated transmembrane protein 4-beta

Raised in

Rabbit

Species Reactivity

Human

Immunogen

Recombinant Human Lysosomal-associated transmembrane protein 4B protein (174-226AA)

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

The LAPTM4B Antibody (Product code: CSB-PA774814LA01HU) is Non-conjugated. For LAPTM4B Antibody with conjugates, please check the following table.

Conjugate	Product Code	Product Name	Application
HRP	CSB-PA774814LB01HU	LAPTM4B Antibody, HRP conjugated	ELISA
FITC	CSB-PA774814LC01HU	LAPTM4B Antibody, FITC conjugated
Biotin	CSB-PA774814LD01HU	LAPTM4B Antibody, Biotin conjugated	ELISA

Clonality

Polyclonal

Isotype

IgG

Purification Method

>95%, Protein G purified

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Tested Applications

ELISA, WB, IHC, IF

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:500-1:1000
IF	1:50-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Background

Function

Required for optimal lysosomal function. Blocks EGF-stimulated EGFR intraluminal sorting and degradation. Conversely by binding with the phosphatidylinositol 4,5-bisphosphate, regulates its PIP5K1C interaction, inhibits HGS ubiquitination and relieves LAPTM4B inhibition of EGFR degradation. Recruits SLC3A2 and SLC7A5 (the Leu transporter) to the lysosome, promoting entry of leucine and other essential amino acid (EAA) into the lysosome, stimulating activation of proton-transporting vacuolar (V)-ATPase protein pump (V-ATPase) and hence mTORC1 activation. Plays a role as negative regulator of TGFB1 production in regulatory T cells. Binds ceramide and facilitates its exit from late endosome in order to control cell death pathways.

Gene References into Functions

our results illustrate the LAPTM4B gene as a diagnostic biomarker in patients with hepatocellular carcinoma having documented evidence of chronic hepatitis C virus infection PMID: 29882487
that LAPTM4B plays an important role in the promotion of hepatocarcinogenesis and cancer progression and may serve as a biomarker for the diagnosis and monitoring of hepatocellular carcinoma PMID: 29108920
Findings suggest that lysosome-associated transmembrane protein 4B (LAPTM4B), vascular endothelial growth factor (VEGF), and nuclear survivin expression are significantly correlated in breast cancer, which may be predictive of prognosis as well as effective therapeutic targets for anticancer therapies. PMID: 28476037
LAPTM4B-35 is a novel cancer-driving protein that can be inhibited by ethylglyoxal bisthiosemicarbazon PMID: 27542271
The overexpressed LAPTM4B-35 was an independent prognostic biomarker for non-small-cell lung cancer, which could predict cancer recurrence and poor over survival. PMID: 27486880
The findings of this study showed LAPTM4B-35 to be strongly associated with tumor proliferation, tumor angiogenesis and poor outcomes of GBM patients. PMID: 28097442
Findings suggested that LAPTM4B allele *1 was a risk factor associated with poor prognosis in patients with colon cancer, but not in patients with rectal or esophageal cancers. LAPTM4B genotype status might be a useful prognostic indicator for patients that need surgical operation in colon cancer. PMID: 27391361
These findings indicate that the LAPTM4B*2 allele is associated with the high risk of pancreatic carcinoma and carrying LAPTM4B*2 may be a susceptible factor to Chinese pancreatic carcinoma patients PMID: 28618967
High expression level of LAPTM4B predicts tumor metastatic potential in patients with breast cancer. PMID: 28245476
Cox analysis demonstrated that combined LAPTM4B-35 and VEGF expression was an independent factor for both OS and DFS (P = 0.015 and P = 0.016, respectively). Overexpression of LAPTM4B-35combined with positive VEGF expression may serve as a new biological marker to predict the prognosis of cervical carcinoma patients. PMID: 26526574
Compared with the control cells, the LAPTM4B-miRNA-transfected NIH:OVCAR3 cells exhibited significant decreases in cell motility and invasion. Furthermore, LAPTM4B depletion resulted in a significant decrease in proliferating cell nuclear antigen, vascular endothelial growth factor, MMP2, MMP9, and CDK12 expression PMID: 26247403
Findings provide evidence that LAPTM4B plays an important role in promoting tumor angiogenesis. PMID: 26383850
Our study points to the relevance of LAPTM4B expression to NSCLC pathogenesis as well as to the probable role of LAPTM4B/NRF2 signaling in promoting lung cancer cell survival. PMID: 26343532
LAPTM4b recruits LAT1-4F2hc to lysosomes, leading to uptake of leucine into lysosomes. PMID: 25998567
These findings indicate that LAPTM4B-35 overexpression may be related to GC progression and poor prognosis, and thus may serve as a new prediction marker of prognosis in GC patients. PMID: 25849595
Authors found that restoration of miR-188-5p can inhibit the PI3K/AKT signaling pathway via the suppression of LAPTM4B. PMID: 25714029
LAPTM4B-35 overexpression is associated with small cell lung cancer. PMID: 25910706
LAPTM4B-35 over-expression was an independent factor in gastric carcinoma prognosis PMID: 25689860
By compartmentalizing ceramide, LAPTM4B controls key sphingolipid-mediated cell death mechanisms and emerges as a candidate for sphingolipid-targeting cancer therapies. PMID: 26280656
LAPTM4B binds to GARP and is a negative regulator of TGF-beta1 production in human Tregs PMID: 26126825
no association between LAPTM4B polymorphism and the risk of breast cancer in a sample of Iranian population PMID: 25001088
Overexpression of LAPTM4B protein is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer. PMID: 24816841
The results reveal an essential layer of EGFR trafficking regulated by LAPTM4B, PtdIns(4,5)P2 signaling, and the ESCRT complex and define a mechanism by which the oncoprotein LAPTM4B can transform cells and promote tumor progression. PMID: 25588945
LAPTM4B-35 is consistently expressed in gastric cancer and is associated with specific clinicopathological and immunohistochemical characteristics. PMID: 25416438
The results suggest that LAPTM4B polymorphisms may be a prospective marker for evaluating the risk and prognosis of non-small cell lung cancer. PMID: 24676601
Overexpression of LAPTM4B-35 may be associated with tumor progression and poor prognosis in prostate cancer. PMID: 24651764
The LAPTM4B *2 allele was associated with increasing risk of multiple cancers, tumor initiation and development in Chinese populations. [meta-analysis] PMID: 24746178
LAPTM4B, with increased expression in airways at shorter distance from tumors, was upregulated in human immortalized cells compared with normal bronchial epithelial cells and promoted anchorage-dependent and independent lung cancer cell growth. PMID: 24563515
LAPTM4B was found to not exhibit any expression changes between different classes of pituitary adenomas. PMID: 23023342
SNPs in lysosomal-associated transmembrane protein 4 beta (LAPTM4B) and insulin-like growth factor 1 (IGF1) were associated with both susceptibility to and curve severity in adolescent idiopathic scoliosis in Korea. PMID: 23364988
study identified the core promoter region responsible for constitutive expression of LAPTM4B and clarified that CREB1 played an important role in LAPTM4B transcriptional regulation in human breast cancer cells PMID: 23469012
LAPTM4B allele *2 may be a risk factor associated with genetic susceptibility to GBC. PMID: 22302286
Endometrial carcinoma patients with LAPTM4B *2 variant had both significantly shorter overall survival and disease-free survival. PMID: 23312008
The results of our study indicated that the polymorphism of LAPTM4B gene did not influence the susceptibility of nasopharyngeal carcinoma in the Chinese population PMID: 23345117
allele *2 of LAPTM4B appears to be associated with genetic susceptibility of HCC and may therefore be considered as a risk factor. PMID: 22207410
High LAPTM4B expression is associated with lymph node metastasis, and recurrence in breast cancer. PMID: 23292099
LAPTM4B*2 is a risk factor associated with breast cancer susceptibility and poor prognosis PMID: 22984585
Data suggest that lysosomal protein transmembrane 4 beta (LAPTM4B) status may be useful in preoperative evaluation of the operability of gallbladder carcinoma (GBC). PMID: 22984631
LAPTM4B-35 was found to be present at high levels in a large proportion of patients with pancreatic carcinoma, and was closely related to disease progression and poor prognosis. PMID: 22971479
LAPTM4B overexpression is an independent factor in poor colorectal cancer prognosis, and it may be an important potential biomarker. PMID: 22578410
LAPTM4B allelic variation was significantly associated with breast cancer occurrence, with adjusted odds ratios of 1.387 (95%CI = 1.111-1.730) for LAPTM4B*1/2 and 1.592 (95% CI = 1.043-2.430) for LAPTM4B*2/2 genotype. PMID: 22270081
gene polymorphism of LAPTM4B may influence the individuals' susceptibility to primary liver cancer. PMID: 22156622
LAPTM4B expression was found to have a significant inverse correlation on prognosis in patients with metastatic ovarian tumors and may be an independent prognostic marker for metastatic ovarian tumors. PMID: 22193644
LAPTM4B is a risk factor associated with poor prognosis in patients with resected HCC. LAPTM4B status may be useful preoperatively as an adjunct in evaluation of the operability of HCC. PMID: 22509374
Findings indicate that the LAPTM4B 2 allele may be a risk factor for ovarian cancer and may play an important role in genetic susceptibility to ovarian cancer. PMID: 22412199
Data show that LAPTM4B protein was localized in lysosomes where its depletion increased membrane permeability, pH, cathepsin release, and cellular apoptosis. PMID: 22037872
Upregulation of LAPTM4B-35 promotes malignant transformation and liver tumorigenesis. PMID: 21618708
overexpression of LAPTM4B-35 attenuated epirubicin-induced apoptosis of gallbladder carcinoma GBC-SD cells through a mitochondria-dependent pathway PMID: 21429547
the LAPTM4B*2 allele might be a cervical cancer risk factor and may play an important role in genetic susceptibility to cervical cancer in the Chinese population. PMID: 21656743
Over-expression of LAPTM4B is associated with chemotherapy resistance and stages III and IV epithelial ovarian cancer PMID: 21416470

Hide All

Subcellular Location

Endomembrane system; Multi-pass membrane protein. Late endosome membrane. Cell membrane. Cell projection. Lysosome membrane. Endosome membrane. Endosome, multivesicular body membrane. Endosome, multivesicular body lumen.

Protein Families

LAPTM4/LAPTM5 transporter family

Database Links

HGNC: 13646

OMIM: 613296

KEGG: hsa:55353

STRING: 9606.ENSP00000402301

UniGene: Hs.492314

Place an order now

I. Product details

Product name *

Code *

Size *

Quantity *

Message

II. Contact details

Name *

Email address *

Company/Organization

Phone

III. Ship To

Address *

City *

State/Province *

Zip/Post code *

Country *

Attn Name *

Phone# *

IV. Bill To Same as Shipping Address

Address *

City *

State/Province *

Zip/Post code *

Country *

Attn Name *

Phone# *

CAPTCHA verification *

Code	CSB-PA774814LA01HU
Size	US$166
	Order now
Image	Western Blot Positive WB detected in: MCF-7 whole cell lysate All lanes: LAPTM4B antibody at 4.8μg/ml Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 42, 26, 36 kDa Observed band size: 42 kDa IHC image of CSB-PA774814LA01HU diluted at 1:600 and staining in paraffin-embedded human lung cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system. IHC image of CSB-PA774814LA01HU diluted at 1:600 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system. Immunofluorescence staining of SH-SY5Y cells with CSB-PA774814LA01HU at 1:200, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
The Latest Promotion
Have Questions?	Leave a Message or Start an on-line Chat

LAPTM4B Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background